 Home > Medical News > Latest Medical News > The first in China!

The first in China!

 Last Update: 2022-01-01
 Source: Internet
 Author: User

Tags

alere drug test

tramadol drug

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Article source: Medical Rubik's Cube Info

Author: Sunshine

Recently, the official website of CDE showed that the clinical trial application for IPG1094 tablets of Aimefel Biosciences has been approved by the China Food and Drug Administration for the treatment of solid tumors and multiple myeloma

IPG1094 is a "First-in-Class" drug independently developed by Aimefe, which targets MIF.

MIF is the only cytokine with enzymatic activity.

It is worth noting that on August 14 this year, the IND application for IPG1094 was approved by the US FDA for indications for solid tumors, hematomas, psoriasis and multiple sclerosis

In addition to IPG1094, the drug in the clinical stage of Aimefe’s R&D pipeline is also the small molecule inhibitor IPG7236, which targets the chemokine CCR8, which has been approved by the FDA for clinical trials

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.